Adjuvant therapy for breast cancer — results from the USA consensus conference

被引:50
作者
Jeffrey S. Abrams
机构
[1] National Cancer Institute,Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis
关键词
Breast cancer; Adjuvant treatment; Chemotherapy; Hormonal therapy;
D O I
10.1007/BF02967528
中图分类号
学科分类号
摘要
The National Institutes of Health, USA sponsored a Consensus Development Conference on November 1-3, 2000 to review several major questions regarding the adjuvant treatment of breast cancer. A non-governmental group of oncology experts was selected to review clinical trial data and judge the evidence presented by 33 breast cancer researchers. Their conclusions resulted in the following recommendations: (1) Prognostic factors critical for determining risk of recurrence are age, axillary lymph node status, tumor size, histologic type and grade and hormone receptor status. (2) Tamoxifen, administered for 5 years, significantly improves long-term survival for women of all age groups with hormone receptor-positive tumors. Ovarian ablation also prolongs survival in premenopausal women. (3) Multi-agent chemotherapy of 4-6 months duration is associated with an improvement in survival in both hormone receptor-positive and -negative tumors. Anthracyclinecontaining regimens offer the greatest survival advantage. The role of taxanes is uncertain but they may be useful in selected patients with node-positive tumors. Women with small, node-negative tumors, women over age 70, and those with tumors of favorable histologic subtype (mucinous or tubular) may not require chemotherapy. (4) Adjuvant radiotherapy to the regional lymph nodes and chest wall following mastectomy is indicated for women with 4 or more axillary nodes. (5) Physicians should employ effective visual aids to help them present a complete and balanced view of the absolute benefits versus the side-effects of adjuvant treatments. Important avenues of future research were also discussed and suggestions were made.
引用
收藏
页码:298 / 304
页数:6
相关论文
共 82 条
[1]  
Moxley JH(1980)Treatment of primary breast cancer: Summary of the National Institutes of Health Consensus Development Conference JAMA 244 797-803
[2]  
Allegra JC(1985)Adjuvant Therapy for Breast Cancer, November 1-3, 2000 Adjuvant chemotherapy for breast cancer.JAMA 254 3461-3463
[3]  
Henney J(1991)Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999 Treatment of early-stage breast cancer.JAMA 265 391-395
[4]  
Fitzgibbons PL(2001)Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer J Natl Cancer Inst 93 979-989
[5]  
Page DL(2000)Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Arch Pathol Lab Med 124 966-978
[6]  
Weaver D(2000)Tamoxifen for early breast cancer: an overview of the randomized trials N Engl J Med 342 525- 533
[7]  
Braun S(2000)Chemotherapy with or without tamoxifen for patients with ER-negative breast cancer and negative nodes: Results from NSABP B-23 Lancet 55 1869-1874
[8]  
Pantel K(1998)CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102 Lancet 351 1451-1467
[9]  
Muller P(2000)Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer Proc Am Soc Clin Oncol 19 72a-72a
[10]  
Aebi S(1998)Postchemotherapy adjuvant tamoxifen beyond five years in patients with lymph node-positive breast cancer Proc Am Soc Clin Oncol 17 1a-1a